Merck & Co. has agreed to acquire Cidara Therapeutics for approximately $9.2 billion, the companies said, in a deal designed to bolster the buyer’s antiviral portfolio with a Phase III drug designed ...

Merck & Co. is buying the developer of an experimental antiviral drug designed to prevent the flu, as the drugmaker aims to ...

Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...

Dow Jones stock Merck topped third-quarter forecasts on Thursday, but shares skidded as its challenges with vaccine Gardasil continued.

Merck (NYSE:MRK) and a plaintiff who is suing the drugmaker over allegations that the Gardasil HPV vaccine she received as a teen caused her heart issues and nerve pain have agreed to adjourn the ...

Merck & Co. Inc. (NYSE:MRK) ranks among the best long-term stocks to buy according to D. E. Shaw. On October 30, Merck & Co.

While the company’s sales outlook was otherwise rosy, Merck took sales hits on Gardisil, Proquad, Varivax and Vaxneuvance.

Merck & Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed second-quarter earnings picture, with adjusted earnings surpassing analyst ...

(Reuters) -A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers caused by the human papillomavirus and ...

At its sprawling complex in Durham, N.C., Merck has opened a new $1 billion, 225,000-square-foot manufacturing plant slated to produce bulk substance for its megablockbuster HPV vaccine Gardasil.

With vaccine sales on the decline, these are tough times for Merck to launch its new pneumococcal shot Capvaxive. | With vaccine sales on the decline across the industry, these are tough times for ...

A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers caused by the human papillomavirus and one of the ...